

REMARKS

In response to the Restriction Requirement dated October 3, 2005, Applicants hereby elect Group I, was initially defined as being inclusive of Claims 1-22 and 28, drawn to methods, for examination. This election is made without traverse. Applicants note that Claims 23-27 depend from method Claim 1, but recited "solutions." Applicants have amended Claims 23-27 above to correct this typographical error, and submit that as amended elected Group I properly includes method Claims 1-28. Non-elected Claims 29-54 are cancelled in view of the above amendment, without prejudice to refiling in a potential divisional application.

In response to the election of species requirement dated October 3, 2005, Applicants elect for initial examination the following specific combination of agents for use in the claimed methods: phenylephrine and ketorolac. This election is made without traverse. The elected species read on claims 1-3, 6, 7, 10-16, 19, 21, 23, 26 and 28, of which Claims 1, 10-16 and 28 are generic.

Examination of all elected claims is respectfully requested.

Respectfully Submitted,


OMEROS CORPORATION



Marcia S. Kelbon
Vice President, Patent & General Counsel
Registration No. 34,358
Direct Dial No. 206.676.5020

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

3/29/06
Date


Stephanie Jansen

MSK:sj

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688